Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06221670
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-24
First Post:
2024-01-14
Brief Title:
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations EGFR or ALK
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Efficacy and Safety of Toripalimab Adjuvant Therapy in High-risk Stage IA2-IB NSCLC With no Driver Alterations EGFR or ALK After Complete Resection a Prospective Single-arm Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective open single-center single-arm phase II clinical study in non-small cell lung cancer NSCLC without common EGFR-sensitive mutations Ex19del and L858R or ALK fusion variants identified in the central laboratory To evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None